[1] |
Kutikov A,Uzzo RG.The R.E.N.A.L.nephrometry score: a comprehensive standardized system for quantitating renal tumor size,location and depth[J].J Urol,2009,182(3): 844-853.DOI: 10.1016/j.juro.2009.05.035.
|
[2] |
徐楚潇,马潞林.肾癌立体定向体部放疗的研究进展[J].现代泌尿外科杂志,2020,25(1): 79-83.Xu CX,Ma LL.Research progress of stereotactic body radiotherapy for renal cell carcinoma[J].J Mod Urol,2020,25(1): 79-83.
|
[3] |
王波,郑军华.冷冻消融治疗肾癌新进展[J/OL].中华腔镜泌尿外科杂志(电子版),2011,5(1): 74-76.DOI: 10.3877/cma.j.issn.1674-3253.2011.01.021.Wang B,Zheng JH.New progress of cryoablation in the treatment of renal cancer[J/OL].Chin J Endourol Electron Ed,2011,5(1): 74-76.DOI: 10.3877/cma.j.issn.1674-3253.2011.01.021.
|
[4] |
孙振层,王睿,蒋晓鸣,等.肾癌根治术后辅助替雷利珠单抗免疫治疗的临床疗效及生存分析[J].中国肿瘤外科杂志,2022,14(5): 494-497,520.DOI: 10.3969/j.issn.1674-4136.2022.05.016.Sun ZC,Wang R,Jiang XM,et al.Clinical efficacy and survival analysis of adjuvanttislelizumab immunotherapy after radical resection of renal cell carcinoma[J].Chin J Surg Oncol,2022,14(5):494-497,520.DOI: 10.3969/j.issn.1674-4136.2022.05.016.
|
[5] |
Shepherd STC,Drake WM,Turajlic S.The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?[J].Eur J Cancer,2023,182: 15-22.DOI: 10.1016/j.ejca.2022.12.011.
|
[6] |
Binderup MLM,Jensen AM,Budtz-Jørgensen E,et al.Survival and causes of death in patients with von Hippel-Lindau disease[J].J Med Genet,2017,54(1): 11-18.DOI: 10.1136/jmedgenet-2016-104058.
|
[7] |
Lonser RR,Glenn GM,Walther M,et al.Von hippel-lindau disease[J].Lancet,2003,361(9374): 2059-2067.DOI: 10.1016/s0140-6736(03)13643-4.
|
[8] |
Malek RS,Omess PJ,Benson RC Jr,et al.Renal cell carcinoma in von hippel-lindau syndrome[J].Am J Med,1987,82(2): 236-238.DOI: 10.1016/0002-9343(87)90062-3.
|
[9] |
Chittiboina P,Lonser RR.Von hippel-lindau disease[J].Handb Clin Neurol,2015,132: 139-156.DOI: 10.1016/B978-0-444-62702-5.00010-X.
|
[10] |
Jilg CA,Neumann HPH,Gläsker S,et al.Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma;clinicopathological long-term follow-up[J].Fam Cancer,2012,11(3):387-394.DOI: 10.1007/s10689-012-9525-7.
|
[11] |
努尔艾力·排尔哈提,展昭兴,王令令,等.肾癌合并静脉癌栓的诊疗进展[J/OL].中华腔镜泌尿外科杂志(电子版),2022,16(5):459-462,471.DOI: 10.3877/cma.j.issn.1674-3253.2022.05.019.Paierhati N,Zhan ZX,Wang LL,et al.Progress in diagnosis and treatment of renal cell carcinoma complicated with venous tumor Thrombus[J/OL].Chin J Endourol Electron Ed,2022,16(5): 459-462,471.DOI: 10.3877/cma.j.issn.1674-3253.2022.05.019.
|
[12] |
Margulis V,Tamboli P,Jacobsohn KM,et al.Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma[J].BJU Int,2007,100(6):1235-1239.DOI: 10.1111/j.1464-410X.2007.07225.x.
|
[13] |
Berg S,Jacobs SC,Cohen AJ,et al.The surgical management of hereditary multifocal renal carcinoma[J].J Urol,1981,126(3): 313-315.DOI: 10.1016/s0022-5347(17)54500-0.
|
[14] |
Reed AB,Parekh DJ.Surgical management of von hippel-lindau disease: urologic considerations[J].Surg Oncol Clin N Am,2009,18(1): 157-174,x.DOI: 10.1016/j.soc.2008.08.005.
|
[15] |
Ganeshan D,Menias CO,Pickhardt PJ,et al.Tumors in von hippellindau syndrome: from head to toe-comprehensive state-of-theart review[J].Radiographics,2018,38(3): 849-866.DOI: 10.1148/rg.2018170156.
|
[16] |
Peraire Lores M,Domínguez J,Bravi CA,et al.Robot-assisted sutureless partial nephrectomy for the treatment of fifteen bilateral renal masses in a patient with Von Hippel-Lindau syndrome: a case report from a high-volume robotic center[J].CEN Case Rep,2023,12(3): 335-340.DOI: 10.1007/s13730-022-00770-7.
|
[17] |
Huang J,Wang Y,Xu F,et al.Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm,phase II trial[J].J Immunother Cancer,2024,12(6): e008475.DOI: 10.1136/jitc-2023-008475.
|
[18] |
Gu L,Peng C,Liang Q,et al.Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena Cava tumor Thrombus: NEOTAX,a phase 2 study[J].Signal Transduct Target Ther,2024,9(1): 264.DOI: 10.1038/s41392-024-01990-2.
|
[19] |
Torok S,Rezeli M,Kelemen O,et al.Limited tumor tissue drug penetration contributes to primary resistance against angiogenesis inhibitors[J].Theranostics,2017,7(2): 400-412.DOI: 10.7150/thno.16767.
|
[20] |
Duran I,Lambea J,Maroto P,et al.Resistance to targeted therapies in renal cancer: the importance of changing the mechanism of action[J].Target Oncol,2017,12(1): 19-35.DOI: 10.1007/s11523-016-0463-4.
|
[21] |
Buczek M,Escudier B,Bartnik E,et al.Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms[J].Biochim Biophys Acta,2014,1845(1):31-41.DOI: 10.1016/j.bbcan.2013.10.001.
|
[22] |
Coco D,Leanza S.Ex vivo resection for renal cancer: indications and results in specific clinical scenarios[J].Jrenhep,2021,5(2): 6-9.DOI:10.15586/jrenhep.v5i2.109.
|
[23] |
Zhong Z,Jiang H,Chen H,et al.Ex vivo tumor dissection followed by kidney autotransplantation in bilateral wilms tumor[J].Front Pediatr,2023,11: 1120797.DOI: 10.3389/fped.2023.1120797.
|
[24] |
Azhar B,Patel S,Chadha P,et al.Indications for renal autotransplant:an overview[J].Exp Clin Transplant,2015,13(2): 109-114.
|
[25] |
Ploussard G,Droupy S,Ferlicot S,et al.Local recurrence after nephron-sparing surgery in von Hippel-Lindau disease[J].Urology,2007,70(3): 435-439.DOI: 10.1016/j.urology.2007.04.040.
|
[26] |
中国抗癌协会泌尿男生殖系肿瘤专业委员会肾癌学组.高危非转移性肾癌术后辅助治疗中国专家共识(2020)[J].临床泌尿外科杂志,2021,36(4): 251-258.DOI: 10.13201/j.issn.1001-1420.2021.04.001.Renal Cancer Group of Urology and Andrology Tumor Professional Committee of China Anti Cancer Association.China expert consensus on postoperative adjuvant therapy for high-risk non-metastatic renal cell carcinoma (2020)[J].J Clin Urol,2021,36(4): 251-258.DOI:10.13201/j.issn.1001-1420.2021.04.001.
|